NCT05535231已完成不适用
A Randomized, Double-Blinded, Comparator-Controlled, Crossover Study to Evaluate the Pharmacokinetics of Gaia Full-Spectrum Turmeric Phytocapsules
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Pharmacokinetics- Peak plasma concentration (Cmax)
研究概览
简要总结
Turmeric is recognized as a bioactive compound with potential benefits for human health. This study compares the pharmacokinetic profile of the Turmeric test product to a comparator.
详细描述
This randomized, double-blinded, comparator-controlled, crossover study will compare the pharmacokinetic profile of the Turmeric test product to a comparator.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult participants who are 18 to 49 years of age (inclusive).
- •In good general health (no active or uncontrolled diseases or conditions) and is able to consume the study product.
- •Have a body mass index between 18.5 to 24.9 kg/m2 (inclusive).
- •Have normal or acceptable to the investigator heart rate at screening.
- •Individuals with childbearing potential should have a negative pregnancy test at baseline and must agree to practice an acceptable form of non-hormonal birth control throughout the study, including but not limited to:
- •double-barrier method
- •non-hormonal intrauterine devices
- •complete abstinence from sexual intercourse that can result in pregnancy
- •vasectomy of partner at least 6 months prior to the first dose of study product Individuals with the potential to impregnate others must agree to use condoms or other acceptable methods to prevent pregnancy throughout the study. Complete abstinence from sexual intercourse that can result in pregnancy is also acceptable.
- •Must have suitable veins for repeated venipuncture.
- •Able to swallow pills or capsules whole and without chewing.
- •Willing and able to comply with the protocol, including:
- •Agrees to consume the standardized meals provided at the site during Visit 2 and Visit 3
- •Agrees to fast overnight, i.e., no food or liquids for a minimum of 10 hours prior to dosing (except for water, permitted up to 1-hour prior to dosing) on Visit 2 and Visit 3
- •Agrees to refrain from consuming grapefruit, pomelo, Seville orange, and starfruit containing foods/beverages 7 days prior to Visit 2 and throughout the study
- •Agrees to refrain from caffeine/xanthine and alcohol or alcohol-containing products 48 hours prior to dosing on Visit 2 and Visit 3
- •Agrees to refrain from the use/application of treatments/procedures listed in the protocol
- •Agrees to maintain the same diet and exercise habits throughout the study
- •Agrees not to donate blood or plasma for 30 days after completing the study
- •Able to give voluntary consent
排除标准
- •Participants who are lactating, pregnant or planning to become pregnant during the study.
- •Have a known sensitivity, intolerability, or allergy to any of the standardized study meals/snacks, study products or their excipients.
- •Received a vaccine for COVID-19 in the 2 weeks prior to screening or during the study period, current COVID-19 infections, or currently have the post COVID-19 condition as defined by World Health Organization (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis). Note: screened participants who have received a COVID-19 vaccine 2 weeks prior to screening would be eligible to participate after completing a 14-day washout period.
- •Have uncontrolled or controlled high blood pressure (≥140 systolic or ≥90 diastolic mmHg) at screening.
- •Have a history of heart disease/cardiovascular disease, renal or hepatic impairment/disease, diabetes (Type I or Type II), previously diagnosed or current diagnosis of any psychiatric disorders, unstable thyroid disease, immune disorders and/or immunocompromised (e.g. HIV/AIDS), cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit, or any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential participant at risk because of participation in the study, or influences the results or the potential participant's ability to participate in the study.
- •Major surgery with general anesthesia in the 3 months prior to screening or planned major surgery during the course of the study.
- •Have a history of blood clotting disorders.
- •Reports a significant blood loss or blood donation totaling between 101 mL to 449 mL of blood within 30 days prior to the first pharmacokinetic visit or a blood donation of more than 450 mL within 56 days prior to the first pharmacokinetic visit.
- •Reports donating plasma (e.g., plasmapheresis) within 15 days prior to the first pharmacokinetic visit.
- •Have an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea).
- •Have gallstones, bile duct obstruction, stomach ulcers, excess stomach acid, or gastroesophageal reflux disease.
- •History of alcohol or substance abuse in the 12 months prior to screening or use that to the opinion of the Qualified Investigator may be of a concern for the study.
- •Receipt or use of test product(s) in another research study within 28 days prior to baseline or longer if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study.
- •Any other active or unstable medical conditions or use of medications/supplements/ therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant.
结局指标
主要结局
Pharmacokinetics- Peak plasma concentration (Cmax)
时间窗: 8 hours
Test products Peak plasma concentration (Cmax)
Pharmacokinetics- Time to reach Cmax (Tmax)
时间窗: 8 hours
Test products Time to reach Cmax (Tmax)
Pharmacokinetics- Area under the plasma concentration-time curve for 8 hours (AUC0-8h)
时间窗: 8 hours
Test products area under the plasma concentration-time curve for 8 hours (AUC0-8h)
次要结局
- Pharmacokinetics- Terminal elimination rate constant (Kel)(8 hours)
- Pharmacokinetics- Half-life (T1/2)(8 hours)
- Pharmacokinetics- Total area under the curve (observed from 0-8 hours, and extrapolated from 8 hours to infinity) [AUC(0-∞)](8 hours)
- Safety- participants experiencing adverse events(8 days)
- Safety- adverse events(8 days)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Curcuma Longa L in Rheumatoid ArthritisRheumatoid ArthritisNCT02543931University of Arizona3
已完成
3 期
Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn DiseaseCrohn's DiseaseNCT02255370University Hospital, Clermont-Ferrand61
招募中
不适用
Turmeric for Patients With Basal Joint ArthritisThumb OsteoarthritisNCT03017118Massachusetts General Hospital60
已完成
不适用
Bioavailability of Curcuminoids From Turmipure Gold® in Different Food MatricesHealthyNCT06300021Givaudan France Naturals35
已完成
2 期
Evaluation of the Efficacy of a Turmeric Extract (Arantal®) in Patients With Osteoarthritis of the Knee (Gonarthrosis).Osteoarthritis, KneeNCT00992004Bioxtract SA280